



PTO/SB/30 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request  
for  
Continued Examination (RCE)  
Transmittal

Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

|                        |                        |
|------------------------|------------------------|
| Application Number     | 09/600,786             |
| Filing Date            | 7/21/2000              |
| First Named Inventor   | Alexandros Makriyannis |
| Art Unit               | 1621                   |
| Examiner Name          | Deborah D. Carr        |
| Attorney Docket Number | UCONAP/145/PC/US       |

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a.  Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

i.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_

ii.  Other \_\_\_\_\_

b.  Enclosed

I.  Amendment/Reply      iii.  Information Disclosure Statement (IDS)

ii.  Affidavit(s)/ Declaration(s)      iv.  Other

## 2. Miscellaneous

Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a

a.  Suspension of action on the above license/approval for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  
b.  Other \_\_\_\_\_

3

Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

The Director is hereby authorized to charge the following fees, or credit any overpayments, to

a.  Deposit Account No. 16-2563

i.  RCE fee required under 37 CFR 1.17(e) | 09/19/2005 SDENBOB1 00000009 09600786

ii.  Extension of time fee (37 CFR 1.136 and 1.17) | 01 FC:2801 395.00 OP


iii.  Other \_\_\_\_\_

b.  Check in the amount of \$ 395.00 enclosed

c.  Payment by credit card (Form PTO-2020 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

|                   |   |                  |           |
|-------------------|---|------------------|-----------|
| Signature         |  | Date             | 9-14-2005 |
| Name (Print/Type) | James E. Piotrowski   | Registration No. | 43,860    |

**CERTIFICATE OF MAILING OR TRANSMISSION**

addressed to: Mail Stop RCC, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First applicant: Alexandros Makriyannis

Application No.: 09/600,786      Examiner: Carr, Deborah D

Filing Date: 7/21/2000      TC/A.U.: 1621

Title: Cannabimimetic Lipid Amides As Useful Medications

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

**SUBMISSION WITH RCE**

This paper is the required submission under 37 CFR 1.114 for the Request for Continued Examination (RCE) enclosed herewith.

This submission includes amendment to the:

- specification
- claims
- figures
- abstract
- other: